|1.||Maeda, H: 3 articles (03/2009 - 04/2000)|
|2.||Maeda, Hiroshi: 2 articles (07/2013 - 03/2002)|
|3.||Mi, Zhiping: 2 articles (09/2008 - 02/2006)|
|4.||Nylander, Karen D: 2 articles (09/2008 - 01/2002)|
|5.||Schor, Nina Felice: 2 articles (02/2006 - 01/2002)|
|6.||Liang, Ye: 2 articles (02/2006 - 01/2002)|
|7.||Kobayashi, Shinichiro: 2 articles (03/2003 - 01/2003)|
|8.||Okamoto, Kazuma: 2 articles (03/2003 - 01/2003)|
|9.||Otsuji, Eigo: 2 articles (03/2003 - 01/2003)|
|10.||Toma, Atsushi: 2 articles (03/2003 - 01/2003)|
03/01/1997 - "Targeting studies using the anti-cancer agent neocarzinostatin (NCS), conjugated to anti-bodies have shown relatively poor specificity. "
12/01/1978 - "Phase I study of neocarzinostatin in children with cancer."
09/01/2008 - "To identify and mathematically model molecular predictors of response to the enediyne chemotherapeutic agent, neocarzinostatin, in nervous system cancer cell lines. "
08/01/2003 - "Neocarzinostatin induces an effective p53-dependent response in human papillomavirus-positive cervical cancer cells."
03/01/2003 - "HAMA that had developed after administration of tumor-specific murine monoclonal antibody A7 conjugated with neocarzinostatin were measured in patient serum. "
|2.||Hepatocellular Carcinoma (Hepatoma)
01/01/1980 - "A phase II study of neocarzinostatin (NSC 157365) in malignant hepatoma. "
05/01/1982 - "We named this new method "high pressure one hot injection." When we tried to apply this method to patients with inoperable hepatoma, we considered that Neocarzinostatin (NCS) was a very applicable antitumor drug in terms of cell killing kinetics. "
05/01/1982 - "[Efficacy of arterial infusion chemotherapy with neocarzinostatin on inoperable hepatoma]."
01/01/1981 - "Because of encouraging single-agent activity for both zinostatin and doxorubicin in hepatocellular cancer, a phase I tolerance study with these drugs in combination was undertaken. "
11/01/2010 - "Here, we provide genetic evidence that ATM kinase activity is required to trigger 5-FU- and neocarzinostatin-dependent cFLIP(L) and cFLIP(S) down-regulation, which in turn sensitize hepatocellular carcinoma (HCC) cell lines to TRAIL. "
02/01/1995 - "These observations suggest that the intra-tumoural injection of neocarzinostatin conjugated to MAb A7 offers promise in treating pancreatic carcinoma."
08/01/1983 - "2. Clinical studies on the administration of neocarzinostatin in advanced and recurrent carcinoma of the pancreas]."
09/01/1992 - "Fate of antibody-neocarzinostatin conjugates bound to human colonic carcinoma cells in vitro."
04/01/1990 - "Specific cytotoxic effect of neocarzinostatin conjugated to monoclonal antibody A7 on human pancreatic carcinoma."
08/01/1983 - "1. Administration of neocarzinostatin in advanced and recurrent carcinoma of the stomach]."
|4.||Glioblastoma (Glioblastoma Multiforme)
07/01/1982 - "An antitumor protein, neocarzinostatin (NCS) as a prototype drug, has been utilized since it was found effective against glioblastoma cells at extremely low concentration (less than 5 ng/ml) and it is readily inactivated by serum. "
11/01/1982 - "In vitro study, the minimum susceptibility of glioblastoma cells to neocarzinostatin was found to be below 0.005 microgram/ml, whereas normal glia cells were not affected at 0.3 microgram/ml. This study indicated that neocarzinostatin was extremely effective in the treatment of malignant brain tumor without affecting normal neural tissue. "
11/01/1982 - "Neocarzinostatin as previously reported, appeared to exhibit an intense cytotoxicity to the glioblastoma cells and some other malignant brain tumor cells, such as pineal germinoma or medulloblastoma, which are notoriously known to disseminate into the cerebrospinal fluid space. "
|5.||Urinary Bladder Neoplasms (Bladder Cancer)
06/01/1980 - "Neocarzinostatin demonstrated minimal therapeutic activity (1 partial remission) in patients with bladder cancer. "
01/01/1980 - "Chemotherapy for bladder cancer with neocarzinostatin: evaluation of systemic administration."
06/01/1980 - "Neocarzinostatin (NCZ), a new antitumor antibiotic, was administered to 19 patients with bladder cancer, 16 patients with prostatic cancer, and 3 patients with hepatoma. "
01/01/1997 - "The effects of oxidative stress on double strand DNA breakage were examined in T-24 human bladder tumor cells using various active oxygen producing agents such as hydrogen peroxide (H2O2), bleomycin (BLM), neocarzinostatin (NCS), and x-ray irradiation. "
07/01/1979 - "Of 12 drugs tested, Carboquone, Neocarzinostatin, Actinomycin D, Adriamycin, Mitomycin C and Chromomycin A3 produced intensive cytotoxic effects, while Thio-Tepa, Bleomycin, 5-Fluorouracil and Vincirstine were less cytotoxic, Intravesical instillation of Carboquone, one of the most toxic agents in vitro, resulted in complete or partial tumor remission in 6 of 9 patients with bladder cancer. "
|2.||maleic acid (maleate)
|3.||DNA (Deoxyribonucleic Acid)
|4.||Ethiodized Oil (Ethiodol)
|6.||poly(maleic acid-styrene)neocarzinostatin (zinostatin stimalamer)
|1.||Drug Therapy (Chemotherapy)
|2.||Heterologous Transplantation (Xenotransplantation)
|5.||Combination Drug Therapy (Combination Chemotherapy)